Alisertib
Phase 2Small molecule
TakedaAlisertib is used to treat certain types of cancer, particularly a blood cancer called peripheral T-cell lymphoma. It works by blocking a protein that helps cancer cells divide and grow.[1] Alisertib is currently being investigated across 5 indications[3], with its most advanced program in Phase 2.[1]
Alisertib is one of 150 small molecule programs targeting Breast Carcinoma. It is currently in Phase 2.
5
Indications
54
Total Trials
6
Active Trials
149
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
141 competitors in Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Imfinzi
AstraZenecaPhase 3
Camptosar
PfizerPhase 3
Tecentriq
RochePhase 3
Keytruda
Merck & Co.Phase 3
Vepesid
AAvyxa
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Tarlatamab-Dznl
AmgenPhase 3
Yervoy
Bristol-Myers SquibbPhase 3
Lynparza
AstraZenecaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lymphoma11 trials
Show 8 more trials
Breast Cancer3 trials
Advanced Solid Tumors2 trials
Prostate Cancer2 trials
34 more indications
Colorectal Cancer1 trial
Advanced Malignancies1 trial
Peritoneal Carcinoma1 trial
Glioma1 trial
Patients With Advanced Solid Tumors1 trial
Leukemia1 trial
Induction Chemotherapy1 trial
Hematologic Malignancies1 trial
Myelofibrosis1 trial
Patients With Solid Tumors1 trial
Papilloma1 trial
T-cell non-Hodgkin lymphoma1 trial
Gastrointestinal Tumors1 trial
Myelodysplastic Syndrome1 trial
Esophageal Adenocarcinoma1 trial
Triple-Negative Breast Cancer1 trial
Head and Neck Squamous Cell Cancer1 trial
Pancreatic Cancer1 trial
Leiomyosarcoma1 trial
Malignant Mesothelioma1 trial
Non-Small Cell Lung Cancer1 trial
Hematological Malignancies1 trial
Small Cell Lung Cancer ( SCLC )1 trial
Breast Carcinoma1 trial
Hormone Receptor Positive / HER2-negative Breast Cancer1 trial
Estrogen1 trial
Recurrent B-Cell Non-Hodgkin Lymphoma1 trial
Malignant Rhabdoid Tumor1 trial
Lung Cancer Metastatic1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Alisertib. EMBL-EBI & Wellcome Sanger Institute.
- [4]